Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
A single neurofibroma may not be indicative of this disorder, but multiple tumors are strongly suggestive of NF1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback